Chickenpox vaccine is under clinical development by Beijing Minhai Biotechnology and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Chickenpox vaccine’s likelihood of approval (LoA) and phase transition for Chicken Pox took place on 14 Nov 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Chickenpox vaccine Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Chickenpox vaccine overview
Varicella vaccine is under development for the prevention of chicken pox infection. The drug candidate is a lyophilized live attenuated vaccine. It is administered through subcutaneous route.
Beijing Minhai Biotechnology overview
Beijing Minhai Biotechnology (Minhai), a subsidiary of Shenzhen Kangtai Biological Products Co Ltd is involved in the research, development, production, and marketing of bacteria and virus vaccine products for infectious diseases. Its product line includes Hib conjugate vaccine, DTaP-Hib vaccine, MR vaccine and 23 valent PPSV vaccine. The company’s pipeline products comprise valent PCV, HDCV rabies vaccine, sabin IPV and PENTA among others, which are in pre-clinical trial to New Drug Application (NDA). The company supplies its products through registered distributors across various countries such as Uzbekistan, the Philippines, India, Russia, and Pakistan. Minhai is headquartered in Beijing, China.
Quick View Chickenpox vaccine LOA Data
|Highest Development Stage|